Guselkumab dosing study for moderate-to-severe psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with plaque-type psoriasis (the most common form) for at least 6 months
- Moderate-to-severe psoriasis covering at least 10% of your body, or with significant severity scores
- No active tuberculosis or signs of it
- Not pregnant (or willing to use contraception and get pregnancy tests during the study)
- No serious liver, kidney, heart, or blood disorders
- No cancer in the past 5 years (with some exceptions for skin cancer and cervical cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
This trial is for people with skin psoriasis who are already taking guselkumab (Tremfya) and have their shots spaced 9 weeks or longer apart. Researchers will see how well the skin is controlled with this longer interval.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.